European Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine
The European Commission has imposed fines totalling €427.7m (£340m) on the French pharmaceutical company Servier and five producers of generic medicines — namely Niche/Unichem, Matrix (now part of Mylan), Teva, Krka and Lupin — for concluding a series of deals all aimed at protecting Servier’s bestselling blood-pressure medicine, perindopril, from price competition by generics in the EU. Through a technology acquisition and a series of patent settlements with generic rivals, Servier implemented a strategy to exclude competitors and delay the entry of cheaper generic medicines to the detriment of public budgets and patients in breach of EU antitrust rules.
Perindopril is a blockbuster blood-pressure control medicine and used to be Servier’s bestselling product. Servier’s patent for the perindopril molecule expired, for the most part, in 2003. The European Commission found that in 2004 Servier acquired a protected technology just to stop the generic producers that were preparing their market entry. Servier never used the acquired technology.
The European Commission also found that Servier settled the challenges brought by the generic producers against its patents. The commission held that the settlements were not ordinary transactions where two parties decide to settle a patent claim outside of court to save time and costs. On the contrary, the generic companies agreed to abstain from competing in exchange for a share of Servier’s rent…
Click on the link below to read the rest of the DLA Piper briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
The Australian Taxation Office released a draft ruling on the Goods and Services Tax treatment of bitcoin transactions on 20 August 2014.
DLA Piper’s ‘Life sciences: patent extension strategies and antitrust global update’ video covers global antitrust and competition issues including product hopping and reverse payment patents.
Analysis from The Lawyer
Regulators are ramping up the pressure in the aftermath of recession, leaving firms to compete for compliance and restructuring work
Shearman & Sterling is making its presence felt in the City, squaring up to magic circle firms and looking to muscle in on key relationships. Private equity house Bridgepoint is one outfit that has had its head turned by the US firm.